A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma.

Trial Profile

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Eflornithine (Primary) ; Bortezomib; Crizotinib; Dasatinib; Lapatinib; Sorafenib; Vorinostat
  • Indications Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEDS-PLAN
  • Most Recent Events

    • 13 Feb 2018 Treatment arm has been changed from 1 to 2 and study design has been changed from single group to parallel assignment. Planned patient number has been increased. Phase has been changed from I to II.
    • 13 Feb 2018 Planned number of patients changed from 24 to 500.
    • 13 Feb 2018 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top